Type 2 diabetes is common enough among Medicare enrollees that a single pill’s price can move real money through the Part D program. Starting January 1, the government-set price for a month’s supply of the diabetes drug Tradjenta drops from $488 to $78, an 84% cut that comes from the second round of Medicare’s drug price negotiations rather than from any change the manufacturer made on its own. Close to 280,000 people with Medicare take the drug, according to the same federal accounting that set the new price.
How $488 Became $78
The $488 figure is the list price CMS used as the negotiation’s starting point, and $78 is what the agency calls the maximum fair price, the ceiling a plan will pay once the new rate takes hold. CMS’s fact sheet on negotiated prices for 2027 lists Tradjenta’s reduction at 84%, among the larger cuts in a round of 15 drugs that ranged from a 38% reduction on one drug to an 85% reduction on another. Both prices in the fact sheet represent the same unit of measurement, so the comparison holds regardless of which specific dose or package size a given prescription uses. The new price takes effect on January 1, 2027, the same date every other drug in this negotiation cycle changes price at once.
Inside the kit: 51 state Medicare cost-help packs, the new Part D out-of-pocket cap, the prior-authorization appeal steps and a medication and cost tracker sit alongside each other, useful once a price like Tradjenta’s changes and a household wants to see how that shift lines up against everything else on a drug list. Open The Medicare Cost & Coverage Protection Kit.
Why Tradjenta Made the Negotiation List
CMS does not negotiate every drug Medicare covers; it selects drugs based on total Part D spending and the number of people taking them. The agency’s companion selected-drug-list fact sheet ties Tradjenta specifically to type 2 diabetes treatment and records roughly $1.15 billion in Part D spending on the drug and about 278,000 Medicare beneficiaries using it during the accounting period CMS reviewed. That combination of a widely prescribed condition and a nine-figure annual spending total is exactly the profile CMS’s selection criteria are built to catch, and it is why a once-daily diabetes pill sits on the same list as far more expensive cancer and autoimmune treatments negotiated in the same round. A pill taken every day for years, rather than for a short course of treatment, can rack up hundreds of millions of dollars in Part D spending even though its individual price is far lower than a cancer drug’s monthly cost, simply because so many more people are filling it every month. The other 14 drugs in this negotiation cycle span a wider range of conditions, from asthma and COPD inhalers to treatments for blood cancers, but CMS’s selected-drug-list fact sheet shows each one qualified the same way Tradjenta did: enough total Medicare spending, concentrated in enough beneficiaries, to meet the program’s statutory selection thresholds.
The Inflation Reduction Act Authority Behind the Price
Medicare could not set these prices at all without the negotiation authority Congress created. CMS’s own program overview page ties the negotiation power to the Inflation Reduction Act, codified at Sections 1191 through 1198 of the Social Security Act, and confirms that the resulting maximum fair prices for this second cycle of 15 Part D drugs take effect January 1, 2027. Tradjenta’s new $78 price is one output of that same statutory process rather than a one-off deal specific to the drug’s manufacturer, which is part of why every other drug on the list changes price on the identical date. The program moves in cycles rather than all at once: this is only the second group of Part D drugs to go through negotiation, following a first cycle whose prices took effect in 2026, and CMS’s own timeline notes that a third round, covering drugs whose negotiated prices begin in 2028, is already under way behind the scenes even as the 2027 prices are finalized.
What Changes for a Part D Enrollee Taking Tradjenta
The price cut applies to what Medicare and a plan pay for the drug, not directly to a pharmacy counter co-pay, though a lower underlying price typically flows through to lower coinsurance for anyone whose cost-sharing is calculated as a percentage of the drug’s price rather than a flat dollar amount. A person filling a Tradjenta prescription in December, before the new price takes effect, is still paying under the old pricing structure, and the change arrives automatically on the new date without any action required at the pharmacy counter. Because Tradjenta is taken daily for an ongoing condition rather than for a short course of treatment, the price change compounds across every refill for as long as the prescription continues, unlike a one-time procedure where a single price change matters only once. That also means the $410 gap between the old and new price is not a single savings event but something that recurs with every monthly fill, month after month, for as long as a person’s treatment plan calls for the drug. CMS’s fact sheet frames the change as part of a broader shift: alongside Tradjenta, the same round of negotiations lowered prices on drugs treating everything from diabetes and psychiatric conditions to lung disease and several forms of cancer, all taking effect on the same January 1 date.
A Lower Price on One Drug, Not on the Whole Bill
An 84% cut on Tradjenta’s price says nothing about what happens to every other prescription on the same Part D plan, and a household juggling several medications rarely tracks all of them against a single fact sheet from CMS. The gap between one drug getting cheaper and a monthly drug bill actually going down depends on what else is on that list and how a plan structures its own cost-sharing.
The Medicare Cost & Coverage Protection Kit tracks that whole list with a medication and cost tracker paired with the new Part D out-of-pocket cap that limits how high the annual total can climb.
See the medication tracker in The Medicare Cost & Coverage Protection Kit.
This article was produced with AI assistance and reviewed by a human editor, using CMS’s own negotiated-price and selected-drug fact sheets.
